Fidaxomicin

Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12?μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research[1][2][3].

O=C(C(C(O)=C(Cl)C(O)=C1Cl)=C1CC)O[C@H]([C@H](O[C@H]2OC/C(C(O[C@](C/C=C3C)([H])[C@H](O)C)=O)=C\C=C\C[C@@H](/C(C)=C\[C@H](CC)[C@@H](O[C@@](OC(C)(C)[C@@H](OC(C(C)C)=O)[C@@H]4O)([H])[C@H]4O)\C(C)=C/3)O)C)[C@@H]([C@@H]2OC)O

[1]Poxton IR, et al. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol. 2010 Apr;5(4):539-48.|[2]Tannock GW, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359.|[3]Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2. |[4]Ackermann G, et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2.